OPC 167832

Drug Profile

OPC 167832

Alternative Names: OPC167832

Latest Information Update: 05 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Otsuka Pharmaceutical; Otsuka Pharmaceutical Development & Commercialization
  • Class Antibacterials; Antituberculars
  • Mechanism of Action DprE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Tuberculosis

Most Recent Events

  • 29 Jan 2018 Otsuka Pharmaceutical receives grant from the Bill & Melinda Gates Foundation for OPC 167832 development in Tuberculosis
  • 29 Jan 2018 Otsuka Pharmaceutical plans a clinical trial for Tuberculosis in the fourth quarter of 2018
  • 29 Jan 2018 Pharmacodynamics data from a preclinical trial in Tuberculosis released by Otsuka Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top